Acronym NA
Category
Marine Biotechnology
Title Development of bioactive hydrolysate from marine by-products Programme National Programme
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
NA
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
NA
Specific Programme (FP7)
NA
Funding source National Coordinator Jaran Rauø Coordinator email NA
Coordinator institution
NA
Institutions involved
NOFIMA - Norwegian Institute of Food, Fisheries and Aquaculture Research (Norway) ,
Start year 2015 End year 2019 Funding (€) € 232,300 Website https://prosjektbanken.forskningsradet.no/en/project/FORISS/245235?Kilde=FORISS&distribution=Ar&chart=bar&calcType=funding&Sprak=no&sortBy=date&sortOrder=desc&resultCount=30&offset=150&ProgAkt.3=BIOTEK2021-Bioteknologi%20for%20verdiskaping&source=FORISS&projectId=294594 Summary A large volume of marine by-products from the Norwegian fishery and fish industry are not exploited or are used to low value products In this project we want to develop and document bioactive products for dietary supplements related to the treatment of conditions related to metabolic syndrome. On the basis of six different marine products from cod, shrimp, snow crab, salmon and algae we will make hydrolysates with different enzymes and with different molecular weights and degree of hydrolysis. The different hydrolysates will be screened for bioactivity related to 1) Diabetes mellitus type 2, 2) High cholesterol (LDL) levels , 3) Appetite regulation and 4) Anti-adipocyte effect. Results will be analyzed with the help of peptide mapping and multivariate analysis prior to new production of hydrolysates based on the analysis followed by a second round of bioactivity screening for the same conditions. One or more hydrolysates, with satisfactory in-vivo bioactivity, will be processed in industrial scale at the National facility for marine bioprocessing (NAMAB) prior to further testing in animal model(s). A preclinical efficacy test, in animal model, is the last step in this project. Interesting effects will as a next step be evaluated for testing in humans (clinical trials). The project has a big potential to create novel products of high value from raw materials which is not exploited or are sold at a very low value. Stella Polaris has through its subsidiary company Marealis AS developed a hydrolysate (peptide concentrate) from shrimp shell with very promising effect on the reduction of elevated blood pressure. The product is currently documented for its effect in a clinical trial. Experience from this development will be used in the PepSea project.
Keywords
Crustacean;
Salmon;
Shrimp;
Cod;
Bioactive compounds;
Biomaterial;
Crab;
Shellfish;
Fish;
Byproducts;
Marine Region
76
Not associated to marine areas
0
Marine Region Map
